KBC Group
PTGX icon

KBC Group’s Protagonist Therapeutics PTGX Stock Holding History

KBC Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$222K Hold
1,574
– – ﹤0.01% 982
2026
Q2 		$193K Hold
1,574
– – ﹤0.01% 1061
2026
Q1 		$166K Hold
1,574
– – ﹤0.01% 1045
2025
Q4 		$137K Hold
1,574
– – ﹤0.01% 1101
2025
Q3 		$105K Hold
1,574
– – ﹤0.01% 1228
2025
Q2 		$87K Sell
1,574
-519
-25% -$24.9K ﹤0.01% 1289
2025
Q1 		$101K Hold
2,093
– – ﹤0.01% 1475
2024
Q4 		$81K Buy
2,093
+737
+54% +$32.1K ﹤0.01% 1676
2024
Q3 		$61K Hold
1,356
– – ﹤0.01% 1624
2024
Q2 		$47K Buy
1,356
+154
+13% +$4.51K ﹤0.01% 1655
2024
Q1 		$35K Buy
+1,202
New +$32.7K ﹤0.01% 1720

Other funds holding PTGX

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

KBC Group's PTGX Position: Q3 2026 in Review

KBC Group held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 1,574 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

KBC Group first reported a position in PTGX in Q1 2024 and has held it in 11 quarters since. 252 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • KBC Group held 1,574 shares of Protagonist Therapeutics worth $222K as of Q3 2026.
  • KBC Group left its Protagonist Therapeutics share count unchanged in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #982 holding.
  • KBC Group first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • 252 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.